



Published in final edited form as:

Nature. 2013 August 15; 500(7462): . doi:10.1038/nature12394.

## Translating Dosage Compensation to Trisomy 21

Jun Jiang<sup>1</sup>, Yuanchun Jing<sup>1</sup>, Gregory J. Cost<sup>2</sup>, Jen-Chieh Chiang<sup>1</sup>, Heather J. Kolpa<sup>1</sup>, Allison M. Cotton<sup>3</sup>, Dawn M. Carone<sup>1</sup>, Benjamin R. Carone<sup>1</sup>, David A. Shivak<sup>2</sup>, Dmitry Y. Guschin<sup>2</sup>, Jocelynn R. Pearl<sup>2</sup>, Edward J. Rebar<sup>2</sup>, Meg Byron<sup>1</sup>, Philip D. Gregory<sup>2</sup>, Carolyn J. Brown<sup>3</sup>, Fyodor D. Urnov<sup>2</sup>, Lisa L. Hall<sup>1</sup>, and Jeanne B. Lawrence<sup>1,\*</sup>

<sup>1</sup>Department of Cell and Developmental Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655

<sup>2</sup>Sangamo BioSciences, 501 Canal Blvd., Richmond, CA 94804

<sup>3</sup>Department of Medical Genetics, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3

### Abstract

Down syndrome (DS) is a common disorder with enormous medical and social costs, caused by trisomy for chromosome 21 (Chr21). We tested the concept that gene imbalance across an extra chromosome can be *de facto* corrected by manipulating a single gene, *XIST*. Using genome editing with zinc finger nucleases, we targeted a large, inducible *XIST* transgene into the Chr21 *DYRK1A* locus, in DS pluripotent stem cells. *XIST* RNA coats Chr21 and triggers stable heterochromatin modifications, chromosome-wide transcriptional silencing and DNA methylation to form a “Chr21 Barr Body.” This provides a model to study human chromosome inactivation and creates a system to investigate genomic expression changes and cellular pathologies of trisomy 21, free from genetic and epigenetic noise. Remarkably, deficits in proliferation and neural rosette formation are rapidly reversed upon silencing one Chr21. Successful trisomy silencing *in vitro* also surmounts the major first step towards potential development of “chromosome therapy”.

---

In the U.S., about 1 in 300 live births carry a trisomy, half of which are for chromosome 21 (Chr21), which causes Down syndrome (DS). DS is the leading genetic cause of intellectual disabilities and the millions of DS patients across the world also face multiple other health issues, including congenital heart defect, hematopoietic disorders, and Early-onset Alzheimer disease<sup>1,2</sup>. DS researchers have sought to define the more “DS critical” genes on

---

\*To whom correspondence and requests for reagents should be addressed: Jeanne.Lawrence@umassmed.edu.

Supplementary Information is available in the online version of the paper.

**Author contributions** JJ with assistance of YJ: designed and produced all constructs, edited all cell lines, designed and performed most experiments. JBL, JJ, LLH: were the main contributors to designing experiments, and interpreting results. JBL, JJ, LLH, & FDU wrote the manuscript. FDU, PDG, GJC: engineered and validated ZFNs. JRP: performed Cell and Southern analysis. JC: performed SNP analysis, characterized three sub-clones, and helped with proliferation experiments. JJ, YJ, with help from JC, MB, HJK & LLH: initial screening of targeted iPSC sub-clones. HJK: edited and characterized primary DS fibroblast line. AMC, CJB: DNA methylation analysis and provided *XIST* cDNA. JJ, FDU: prepared microarray library. DMC and BRC analyzed microarray data with help from DAS, DYG, EJR.

Microarray for 27 samples is deposited in GEO under accession number GSE47014.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Readers are welcome to comment on the online version of the paper.

Requests for ZFNs can be directed to FDU ([furnov@sangamo.com](mailto:furnov@sangamo.com)).

**Conflict of interest statement.** JBL and LLH are the inventors on an issued patent describing the concept of epigenetic chromosome therapy by targeted addition of non-coding RNA. GJC, DAS, DYG, JRP, EJR, PDG, FDU are full-time employees of Sangamo BioSciences.

Chr21, but this has proven difficult due to high genetic complexity and phenotypic variability of DS, confounded by normal variation between individuals<sup>1-3</sup>. Despite progress with DS mouse models<sup>4,5</sup>, there remains critical need for better ways to understand the underlying cell and developmental pathology of human DS, key to therapeutic design of any kind<sup>2</sup>.

The last decade has seen great advances in strategies to correct single-gene defects of rare monogenic disorders, beginning with cells *in vitro* and in several cases advancing to *in vivo* and clinical trials<sup>6</sup>. In contrast, genetic correction of the over-dose of genes across a whole extra chromosome in trisomic cells has remained outside the realm of possibility. Our effort was motivated by the idea that functional correction of living trisomic cells may be feasible by inserting a single gene that can epigenetically silence a whole chromosome. An inducible system for such “trisomy silencing” would have immediate translational relevance as a resource to investigate the cellular pathology and gene pathways impacted in DS, in a setting free from pervasive genetic or epigenetic variation that exists between individuals, sub-clones, or even isogenic cell-isolates<sup>3,7,8</sup>.

Nature has evolved a mechanism to compensate the difference in dosage of X-linked gene copies between mammalian females (XX) and males (XY). This is driven by a large (~17 kb in human) non-coding RNA, *XIST*, which is produced exclusively from the *inactive* X (Xi)<sup>9</sup>, and “paints” (accumulates across) the interphase chromosome structure<sup>10</sup>. During early development, the *XIST* RNA induces numerous heterochromatin modifications and architectural changes which transcriptionally silence the Xi and manifest cytologically as a condensed Barr Body (reviewed in<sup>11,12</sup>). There is evidence for some DNA sequence specificity to *XIST* function, since certain human genes escape X-inactivation<sup>13</sup>; however, autosomal chromatin has substantial capacity to be silenced<sup>14-16</sup>. Understanding the full potential of an autosome to be silenced, however, requires examination under conditions that avoid creating a deleterious functional monosomy. The strategy pursued here meets that requirement and creates a tractable model to study the distinct biology of *human* chromosome inactivation.

As outlined in Figure 1a, we set out to determine if the human X-inactivation gene, *XIST*, could be inserted on one Chr21, and enact a chromosome-wide change in its epigenetic state. We pursued zinc finger nuclease (ZFN)-driven targeted addition<sup>17</sup> of an inducible *XIST* transgene to the gene-rich core of Chr21, in induced pluripotent stem cells (iPSCs), derived from DS patient cells. If accomplished, this milestone would provide a system to study DS cell pathology and the first step towards a potential genetic/epigenetic approach to “chromosome therapy”.

## Insertion of *XIST* into a trisomic Chr21

Given its large size, neither the *XIST* gene nor its cDNA has previously been integrated in a targeted fashion. Thus our first goal was to demonstrate that ZFNs could accurately insert the largest transgene to date, substantially larger than sequences commonly used for genome editing<sup>18</sup>. We first attempted this with a ~16 kb *XIST* transgene in a transformed cell line (HT1080), using established ZFNs to the *AAVS1* locus on Chr19<sup>19</sup>. This proved highly successful (unpublished). To extend this to Chr21, we engineered ZFNs to a 36 bp sequence in intron 1 of the *DYRK1A* locus at Chr21q22 (as in Fig. 1b), and validated their robust activity (Supplementary Fig. 1a, b). We tested an even larger (~21 kb) construct containing near full-length *XIST* cDNA in HT1080 cells and demonstrated efficient, accurate addition to this gene-rich region (Supplementary Fig. 2a, b).

We next determined whether this was achievable in technically challenging iPSCs, which have unique therapeutic and developmental potential to form various cell types, and thus would be important for any future *ex vivo* cellular therapy efforts. We used a male DS iPSC line<sup>20</sup> which we confirmed maintains pluripotency markers and trisomy 21. While a constitutively transcribed transgene could be used, we engineered an inducible system to maximize utility for investigating DS biology. In one step, we integrated both the doxycycline(dox)-controlled *XIST* transgene into Chr21 (Fig. 1b) and a transgene carrying the dox control component (rtTA) into the *AAVS1* Chr19 safe harbor<sup>19</sup> (Supplementary Fig. 3b).

We analyzed 245 colonies from the pooled transformants by interphase *in situ* RNA/DNA FISH (Fig. 1c) to determine if *XIST* was present and overlapped one of three *DYRK1A* alleles. Remarkably, 98.5% of *XIST* RNA-positive colonies carried *XIST* at this location on Chr21, and also contained the rtTA/selection transgene (Supplementary Table 1). Efficiency was sufficiently high that, through modifications to editing conditions, we obtained a few sub-clones with *XIST* integrated into two or even all three alleles of *DYRK1A* (see Methods and Supplementary Fig. 3c and Supplementary Table 1). Six independent sub-clones were chosen for further study based on: an *XIST* transgene on one of three Chr21s, pluripotent colony morphology and OCT4 staining (Fig. 1d and Supplementary Fig. 4a), and formation of embryoid bodies. FISH to metaphase chromosomes (Fig. 1e and Supplementary Fig. 3d) and Southern blotting (Supplementary Fig. 1c–e) confirmed the gene addition accuracy, with 47 chromosomes, for all six clones. High-resolution cytogenetic banding and/or array CGH on selected clones showed no significant abnormalities other than full Chr21 trisomy (Supplementary Fig. 4c–e).

### ***XIST* RNA induces a Chr21 Barr Body**

In the panel of six independent genome-edited clones, we induced transgene expression and detected *XIST* RNA by FISH three days later. A localized *XIST* RNA “territory” over one Chr21 (Fig. 1c) was seen in over 85% of cells in all six clones (Fig. 1d and Supplementary Fig. 4a, b). This mirrored the unique behavior of endogenous *XIST* RNA which “paints” the Xi nuclear territory<sup>10</sup>.

The natural Xi forms a condensed “Barr Body” which carries repressive histone marks<sup>11</sup>. Similarly, five days after *XIST* induction, the edited Chr21 became markedly enriched in all heterochromatin marks examined, including H3K27Me3, UbH2A, and H4K20Me in 90%–100% of cells and, later, with macroH2A (Fig. 2a, b and Supplementary Fig. 5a). Supplementary Figure 5b illustrates that H3K27me spreads across the whole metaphase Chr21. Moreover, Chr21 DNA in many nuclei became notably condensed, further evidence that we successfully generated a heterochromatic “Chr21 Barr Body” (Fig. 2c).

### **Allele-specific silencing across Chr21**

To measure overall transcription across the *XIST*-targeted Chr21, we used an approach we developed to broadly assay nuclear hnRNA expression and to distinguish Xi from Xa<sup>16</sup>, based on *in situ* hybridization to CoT-1 repeat RNA. This showed that the Chr21 *XIST* RNA territory was depleted for hnRNA detected by CoT-1 (Supplementary Fig. 5c), similar to the inactive X chromosome<sup>16</sup>.

We next used multi-color RNA FISH to determine the presence of transcription foci at each allele for six specific Chr21 genes, an established approach we earlier showed discriminates active versus silenced genes on Xi. Without *XIST* expression, there are three bright transcription foci from each *DYRK1A* allele (Fig. 1c, top), but following *XIST* expression,

the targeted allele becomes weaker or undetectable, indicating repression of *DYRK1A* (Fig. 1c, bottom).

The *APP* gene on Chr21 encodes amyloid beta precursor protein; mutations in *APP* which cause accumulation of  $\beta$ -amyloid lead to early onset familial Alzheimer disease (EOFAD), and *APP* over-expression is linked to Alzheimer disease in DS<sup>1</sup>. Initially, three bright RNA transcription foci are apparent (Fig. 3a, top). Short-term *XIST* expression resulted in incomplete repression of the targeted allele (Fig. 3a, middle); which after 20 days was completely silenced, as shown in two independent clones (Fig. 3a, bottom and Fig. 3b).

We examined four more loci, 3 to 21 Mb from *XIST*: *ITSN1*, *USP25*, *CXADR*, and *COL18A1*. Complete silencing of each allele on the edited Chr21 was seen in ~100% of cells accumulating *XIST* RNA (Fig. 3c, d and Supplementary Fig. 6a). Allele-specific silencing was further validated using SNP analysis. RT-PCR products for eight known polymorphic sites (in four genes) were sequenced (*ADAMTS1*, *ETS2*, *TIAMI*, and *HSPA13*) (Supplementary Fig. 6b, c). Interestingly, clones 2 and 3 showed an identical pattern of eight SNP alleles repressed, whereas clone 1 showed an alternate pattern of SNPs repressed. As summarized in Supplementary Fig. 6c, this chromosome-wide pattern allows extrapolation of the haplotype for each of the three Chr21s, and indirectly identifies for each clone which Chr21 was silenced by an *XIST* transgene.

We also examined clones carrying *XIST* on two or all three copies of Chr21 and found that after 20 days in dox, most or all cells lost *XIST* localization or expression, and the targeted chromosomes did not silence the *APP* gene (Supplementary Fig. 7a, b). Thus, there is *in vitro* selection and epigenetic adaptation to circumvent creating a functional monosomy or nullisomy, consistent with observations that monosomic cells do not persist in mosaic patients.

## Genome-wide silencing & methylation

Having demonstrated allele-specific repression for the ten genes examined above, we extended this to genome-wide expression profiling. We treated three transgenic clones and the parental line with dox for three weeks, and compared their transcriptomes to parallel cultures without *XIST*-transcription, all in triplicate. Only on Chr21 is there overwhelming change, in all three clones (Fig. 4a), with ~95% of significantly expressed genes becoming repressed (Supplementary Table 2).

Dosage compensation corrects Chr21 expression to near normal disomic levels, based on the change in total output of expressed genes per chromosome after *XIST* is induced. Since evidence suggests many Chr21 genes are not increased the theoretical 1.5 fold in trisomy<sup>21,22</sup>, we also directly compared trisomic to disomic cells. This provides a baseline for evaluating the degree to which Chr21 over-expression is corrected by *XIST*. After *XIST* induction, overall Chr21 expression is reduced by 20%, 15%, and 19% for clones 1, 2, and 3, respectively; this mirrors very well the 22% reduction for disomic iPSCs that lack the third Chr21 altogether (Fig. 4a). This disomic line is representative, as a similar difference (21%) was seen for another *isogenic* disomic sub-clone we isolated from the trisomic parental iPSCs (not shown). Individual genes repressed by *XIST* distribute across Chr21, as do genes over-expressed in trisomic versus disomic cells (Fig. 4b). In addition, qRT-PCR confirmed repression for individually examined genes (Supplementary Fig. 7c). Clearly, *XIST* induces robust dosage compensation of most Chr21 genes over-expressed in trisomy.

Trisomy 21 may impact genome-wide expression pathways, but differences attributable to trisomy 21 are confounded by genetic and epigenetic variability<sup>21</sup>. This inducible trisomy silencing system provides a new foothold into this important question. For example, even

the three isogenic transgenic sub-clones show many expression differences (>1000), but upon *XIST* induction, ~200 genes change in all three clones (but not the dox-treated parental), most likely directly due to Chr21 over-expression. Therefore, “trisomy correction in a dish” has promise as a means to identify genome-wide pathways perturbed by trisomy 21.

In addition to transcriptional silencing, X-inactivation is stabilized by hypermethylation of promoter CpG islands<sup>23,24</sup>, which occurs late in the silencing process. Therefore, we also examined the promoter methylome in two genome-edited clones three weeks after *XIST* induction and found it largely unaltered, with one striking exception, genes on Chr21 ( $p$  value < 2.2e-16) (Fig. 4c). Here, 97% of CpG-island-containing genes exhibited a robust increase in promoter DNA methylation, within range of that seen for Xi<sup>24</sup> (adjusted for active/inactive chromosomes: see Methods). This change swept the entire chromosome, with the interesting exception of a handful of genes that “escape” methylation in both clones.

In summary, data from eight different approaches demonstrate impressive competence of most Chr21 genes to undergo epigenetic modification and silencing in response to an RNA that evolved to silence the X-chromosome.

## Phenotypic correction *in vitro*

Dosage compensation of chromosome imbalance presents a new paradigm, with opportunities to advance DS research in multiple directions, including a new means to investigate human DS cellular pathologies, which are largely unknown. Inducing trisomy silencing in parallel cultures of otherwise identical cells may reveal cellular pathologies due to trisomy 21, which could be obscured by differences between cell isolates. We examined cell proliferation and neural rosette formation to look for an impact on cell phenotype.

There is some evidence of proliferative impairment in DS brains<sup>4,25</sup>; however, we observed this varied *in vitro* between our DS fibroblast samples, and this would be highly sensitive to culture history. A clear answer emerged from comparing identical cell cultures, grown  $\pm$  dox for one week. *XIST*-induction in six independent transgenic sub-clones rapidly and consistently resulted in larger, more numerous and tightly packed colonies in just seven days (Fig. 5a and Supplementary Fig. 8a), with 18–34% more cells (Fig. 5b). Dox did not enhance growth of the parental DS cells or sub-clone (Fig. 5b and Supplementary Fig. 8a). Thus, a proliferative impairment linked to Chr21 over-expression can be rapidly ameliorated by dosage compensation.

We next examined differentiation of targeted DS iPSCs into neural progenitor cells. In 11–12 days after neural induction of already confluent cultures, all three *XIST*-expressing cultures began to form neural rosettes, and in 1–2 days were replete with neural rosettes (Fig. 5c), a signature of neural progenitors (confirmed by PAX6 and SOX1 staining) (Supplementary Fig. 8b). Remarkably, even at day 14, parallel uninduced cultures remained devoid of rosettes (Fig. 5c). Uncorrected cultures required 4–5 more days in neural-induction media to fill with neural rosettes of similar size and number, as they did on day 17 (Fig. 5d and Supplementary Fig. 8d). There was no effect of dox on neurogenesis in the parental line (Fig. 5c, d and Supplementary Fig. 8d). This marked delay in neural differentiation appears primarily independent of cell proliferation (Methods). Variability in the kinetics of neural differentiation between various iPSC lines would likely obscure differences due to trisomy 21<sup>26</sup>. We circumvented this using parallel cultures and on-demand Chr21 silencing, which made clear these important phenotypic differences. This highlights the potential of this new experimental model to illuminate cellular pathologies directly attributable to Chr21 over-expression in iPSCs and their differentiated progeny.



## Towards future applications

The supplement summarizes two significant points relevant to potential applications and therapeutic strategies. First, we show that heterochromatic silencing is stably maintained, even upon removal of dox and *XIST* expression (Supplementary Fig. 9a, b), consistent with prior studies<sup>23</sup>. Second, while not investigated extensively, we targeted *XIST* in non-immortalized fibroblasts from a female DS patient, which generated many cells carrying *XIST* (and some heterochromatin marks) on Chr21 (Supplementary Fig. 9c, d). Finally, we note that our *XIST* transgene lacks X-chromosome “counting” sequences, and thus is compatible with natural female X-inactivation.

## DISCUSSION

We set out to bridge the basic biology of X-chromosome dosage compensation with the pathology of chromosomal dosage disorders, particularly Down syndrome. In so doing, the present work yields advances that impact three important areas, one basic and two translational.

While not our primary focus here, a significant impact of this work is that we have created a tractable, inducible system to study *human* chromosome silencing. Importantly, unlike random integration into a diploid cell, silencing a trisomic autosome avoids selection against full autosomal silencing, and this demonstrated remarkably robust competence of Chr21 to be silenced. Thus, *XIST* RNA evolved for the X-chromosome utilizes epigenome-wide mechanisms<sup>12</sup>. The ability to insert a single *XIST* transgene in any locus provides a more powerful tool to study *XIST* function, and our effort also almost triples the size of transgenes that can be thus targeted for a host of other compelling applications.

From a translational perspective, trisomy silencing has immediate impact as a new means to define the poorly understood cellular pathways deregulated in DS, and creates the opportunity to derive and study various patient-compatible cell types potentially relevant to DS therapeutics. Inducible “trisomy silencing in a dish” compares otherwise identical cultures, allowing greater discrimination of differences directly due to Chr21 over-expression distinct from genetic and epigenetic variation between transgenic sub-clones, or potentially even rare disomic sub-clones isolated from a trisomic population (<sup>27,28</sup> and this study). *XIST* expression triggers not only Chr21 repression, but a defined effect on the genomic expression profile, and reverses deficits in cell proliferation and neural progenitors, which has implications for hypocellularity in the DS brain<sup>4,25</sup>. This new approach can illuminate the cohort of genes and cognate pathways most consistently impacted in DS, to inform the search for drugs that may rebalance those pathways and cell pathologies. This general strategy could be extended to study other chromosomal disorders, such as trisomy 13 and 18, often fatal in the first 1–2 years.

Finally, the more forward-looking implication of this work is to bring Down syndrome into the realm of consideration for future gene therapy research. While development of any clinical gene therapy is a multi-step process, any prospect requires that the first step, functional correction of the underlying genetic defect in living cells, is achievable. We have demonstrated that this step is no longer insurmountable for chromosomal imbalance in DS. Our hope is that for individuals and families living with DS, the proof-of-principle demonstrated here initiates multiple new avenues of translational relevance for the fifty years of advances in basic X-chromosome biology.

## METHODS

### Cell culture

HT1080 TetR cells (Invitrogen) and Female DS human primary fibroblast line (Coriell) (AG13902) were cultured as recommended by supplier. DS iPSC parental line (DS1-iPS4) was provided by George Q. Daley (Children's Hospital Boston, USA) and maintained on irradiated mouse embryonic fibroblasts (iMEFs) (R & D Systems, PSC001) in hiPSC medium containing DNEM/F12 supplemented with 20% knockout Serum Replacement (Invitrogen), 1mM glutamine (Invitrogen), 100  $\mu$ M non-essential amino acids (Invitrogen), 100  $\mu$ M  $\beta$ -mercaptoethanol (Sigma) and 10 ng/ml FGF- $\beta$  (Invitrogen, PHG0024). Cultures were passaged every 5–7 days with 1 mg/ml of collagenase type IV (Invitrogen).

### ZFN design

ZFNs against the human *AAVSI* locus (*PPP1R12C*) on Chr19 have been previously described<sup>19</sup>. ZFNs against the *DYRK1A* locus were designed using an archive of pre-validated zinc finger modules<sup>18,29</sup>, and validated for genome editing activity by transfection into K562 cells and Surveyor endonuclease-based measurement of endogenous locus disruption ("Cell"<sup>30,31</sup>) exactly as described<sup>29</sup>. Southern blotting for targeted gene addition was performed exactly as described<sup>17,32</sup> on SphI-digested genomic DNA probed with a fragment corresponding to positions Chr21:38825803+38826056 (hg19).

### *XIST* and rtTA/puro plasmid construction

14 kb human *XIST* cDNA, a splicing isoform of full length *XIST* cDNA was subcloned into pTRE3G (Clontech, Cat#: 631167). Two homologous arms (left arm, 690 bp; right arm, 508 bp) of *DYRK1A* gene on Chr21 were amplified by PCR from primary DS fibroblasts (AG13902) (Coriell) and cloned into the pTRE3G vector (Human Chr21 *DYRK1A* left arm primers: forward 5'-GCCGTATACCATTAACCTTTACTGTTC-3', reverse 5'-TCTGTATACGTAAACTGGCAAAGGGGTGG-3'; Human Chr21 *DYRK1A* right arm primers: forward 5'-ATTTTCGCGAACGGGTGATGAGCAGGCTGT-3', reverse 5'-CCGTCGCGAAAACCAGAAAGTATTCTCAG-3'). The pEF1 $\alpha$ -3G rtTA-pA cassette from pEF1 $\alpha$ -Tet3G vector (Clontech) was subcloned into a plasmid for targeted gene addition to the *PPP1R12C/AAVSI* locus<sup>19</sup>, which contains a unique HindIII site flanked by two 800 bp stretches of homology to the ZFN-specified position in the genome.

### Dual-Targeted-addition of human DS iPSCs and generation of stable targeted clones

The DS iPSC line was cultured in 10  $\mu$ M of Rho-associated protein kinases (ROCK) inhibitor (Calbiochem; Y27632) 24 h before electroporation. Single cells ( $1 \times 10^7$ ) were harvested using TryPLE select (Invitrogen), resuspended in 1 x PBS and electroporated with a total of 55  $\mu$ g DNA including five plasmids (*XIST*, *DYRK1A* ZFN1, *DYRK1A* ZFN2, rtTA/puro, and *AAVSI* ZFN) with both 3:1 and 5:1 ratios of *XIST*: rtTA/puro. The electroporation conditions were 220v, and 750  $\mu$ F (BioRad Gene Pulser II System). Cells were subsequently plated on puromycin-resistant DR4 MEF feeders (Open Biosystems, Cat#: MES3948) in hiPSC medium supplemented with ROCK inhibitor for the first 24 h. Over 300 colonies remained after 12 days of 0.4  $\mu$ g/ml puromycin selection and 245 randomly chosen individual colonies across 36 pooled wells were examined by interphase DNA/RNA FISH for the presence and expression of *XIST*, correct targeting and retention of trisomy (since some subclones lacked *XIST* or showed just two *DYRK1A* DNA signals). Over 100 individual clones were isolated and characterized, and those of interest, containing targeted *XIST* on one of three *DYRK1A* loci, were frozen. Six single target clones with good pluripotent morphology, OCT4 positive staining, correct targeting to one trisomic chromosome, and good *XIST* RNA paint were expanded for further characterization. One

double and one triple target line, two non-target clones, and one disomic clone were also isolated and frozen. Targeting and correct chromosome number (47) was confirmed by interphase and metaphase FISH and genome integrity by high resolution G-band karyotype and CGH array.

### Chromosome preparation

iPSCs were treated with 100 ng/ml KaryoMAX colcemid (Invitrogen) for 2–4 h at 37°C in a 5% CO<sub>2</sub> incubator. Cells were trypsinized, treated with hypotonic solution, and fixed with methanol:acetic acid (3:1). Metaphases were spread on microscope slides, and at least 20 analyzed per clone. Karyotype analysis was done on pro-metaphase chromosomes using Standard Giemsa-trypsin G band methods.

### CGH array

CGH was performed in the Cytogenetics Laboratory at UMass Medical School. Genomic Microarray analysis using UMass Genomic Microarray platform (Human Genome Build hg19) was performed with 1 µg of DNA. The array contains approximately 180,000 oligonucleotides (60 mers) that represent coding and noncoding human sequences and high density coverage for clinically relevant deletion/duplication syndromes and the telomeric and pericentromeric regions of the genome. Data was analyzed by BlueFuse Multi, v3.1 (BlueGnome, Ltd).

### DNA/RNA FISH and Immunostaining

DNA and RNA FISH were carried out as previously described<sup>10,15,16,33</sup>. The *XIST* probe is a cloned 14 kb *XIST* cDNA (the same sequence as *XIST* transgene in Fig. 1b) in pGEM-7Zf(+) (Promega). Six Chr21 gene probes are BACs from BACPAC Resources (*DYRK1A*: Rp11-105O24, *APP*: RP11-910G8, *USP25*: RP11-840D8, *CXADR*: RP11-1150I14, *ITSN1*: RP11-1033C16, *COL18A1*: RP11-867O18). DNA probes were labeled by nick translation with either biotin-11-dUTP or digoxigenin-16-dUTP (Roche). In simultaneous DNA/RNA FISH (interphase targeting assay), cellular DNA was denatured and hybridization performed without eliminating RNA and also treated with 2 U/µl of RNasin Plus RNase inhibitor (Promega). For immunostaining with RNA FISH, cells were immunostained first with RNasin Plus and fixed in 4% paraformaldehyde before RNA FISH. Antibodies: H3K27me3 (Millipore, 07–449), UbH2A (Cell Signaling, 8240), H4K20Me (Abcam, ab9051), MacroH2A (Millipore, 07–219), OCT4 (Santa Cruz, sc-9081), PAX6 (Stemgent, 09-0075), SOX1 (R & D Systems, AF3369).

### Allele-specific SNP analysis

Primers were designed to amplify 3' UTR regions of Chr21 genes reported to contain SNPs (Supplementary Table 3). Total cDNA was used from three transgenic clones with and without *XIST* induction for 22 days. RT-PCR products were sequenced by GENEWIZ. Of ~10 genes examined, four were heterozygous and informative in the patient DS iPSC line used here.

### Microarray analysis

Three independently targeted subclones plus the parental Chr21 trisomic (non-targeted) iPSC line were grown ± dox (2 µg/ml) for 22 d. Normal male iPSC and disomic isogenic lines were also cultured for 22 d and total RNA was extracted with a High Pure RNA extraction kit (Roche) in triplicate for each, processed with a Gene Chip 3' IVT Express Kit (Affymetrix), and hybridized to Affymetrix human gene expression PrimeView arrays. Array normalization was performed with Affymetrix Expression Console Software with Robust Multichip Analysis (RMA)<sup>34</sup>. Probesets with the top 60% of signal values were



considered present and “expressed” and were used for all further analysis. Data in Figure 4 has no other threshold applied. When designated, a gene expression change significance threshold was applied using a two-tailed T-test comparing samples  $\pm$  dox in triplicate (N=3) (Supplementary Table 2.  $p < 0.01$ ). For the ~200 genes found to significantly change in all three clones (in text), a T-test with  $p < 0.001$  was applied.

**Microarray Data Interpretation.**—Using extraction-based methods, changes on just one of three alleles (from the *XIST*-bearing chromosome) will be diluted by the other two. If all three chromosomes are fully expressed, this would predict a 33% reduction in Chr21 expression levels per cell when one Chr21 is fully silenced. However, 33% would apply only if Chr21 genes are fully over-expressed to start, and prior evidence and results in this study show this is not the case for many genes. Previous microarray studies have analyzed expression levels of Chr21 in DS patient cells, although such analyses are hampered by the extensive genetic and epigenetic differences between any two individuals<sup>3</sup>. The fraction of Chr21 genes detected as over-expressed varies with the study and tissue, but generally is in the 19–36% range<sup>3,22</sup>, with individual gene increases often in the ~1.2–1.4 range (less than the theoretical 1.5). For example, one study of DS embryoid bodies showed only 6–15% of genes appeared significantly up-regulated, but this was comparing non-isogenic samples of different ES cell isolates<sup>22</sup>.

Our trisomy correction system allows direct comparison of the *same cells* grown in identical parallel cultures, with and without *XIST*-mediated chromosome silencing. Our data shows a ~20% reduction in Chr21 expression overall; importantly this level of reduction is seen either when the third chromosome is silenced in trisomic cells, or when disomic and trisomic cells are compared. This 20% reduction represents an average per cell for all three chromosomes, but corresponds to a 60% reduction in expression for just one Chr21 (the one silenced by *XIST* RNA, as shown here).

Apart from our goal here of trisomy dosage compensation, these results add significantly to understanding the extent of Chr21 over-expression in Down syndrome, by providing a more comprehensive analysis which shows expression of most genes is increased, but less than the theoretical 1.5 fold.

### qRT-PCR

qRT-PCR was performed for eight down-regulated Chr21 genes determined by microarray on an BIO-RAD MyiQ™ Real-Time PCR Detection System in triplicate for clone 3 with/without dox treatment for 22 d. The  $\beta$ -actin gene was used as an internal standard for calculation of expression levels. Primers for eight Chr21 genes and  $\beta$ -actin were described in Supplementary Table 4.

### DNA Methylation analysis

The parental line and two independent targeted lines were grown with and without dox for 22 d, in duplicate cultures. Genomic DNA was extracted using PureLink Genomic DNA Mini Kit (Invitrogen) and 750 ng bisulfite modified with the Alternative Incubation Conditions from the EZ DNA Methylation Kit (Zymo Research). 160 ng of bisulfite DNA was amplified, fragmented and hybridized to Illumina Infinium HumanMethylation450 array following standard protocol as outlined in the user guide. CpG islands were defined as high and intermediate CpG densities using the CpG density classifications based on those used by Weber et al<sup>35</sup>. The program CpGIE was used to locate HC and IC islands on the X chromosome and chromosomes 21 and 22. When multiple probes in CpG islands were associated with the same TSS, an average genic methylation value calculated. These average

genic values were compared pre and post dox induction using the Mann-Whitney test. Analysis was based on CpG islands within promoters of 143 Chr21 genes (Fig. 4c).

The average methylation value was 6% on Chr21 before *XIST* induction, and increased to 20–21% in both subclones after induction. Since any methylation increase on the transgenic chromosome would be diluted by the presence of three Chr21s, this suggests the range of 60% methylation on the one *XIST*-coated chromosome, which is within the range seen for the inactive X chromosome<sup>24</sup>.

### Cell proliferation analysis

Eight different iPSC lines (parental line, one non-targeted subclone, and six independent targeted subclones) were passaged onto 6-well plates at equal cell densities per well of each line and grown  $\pm$  dox for 7 d. At least four replicates of each line were analyzed in two independent experiments. Rigorous measures were taken to minimize and control for any minor variations in seeding densities of iPSCs, which cannot be plated as single cell suspensions. First, the analysis was done twice for six different transgenic clones, in each case comparing triplicate plates of corrected versus not corrected (dox versus no dox). To avoid differences in plating efficiencies of dox and no dox cells, we performed the experiments over a time course that did not require passage. For each of the six transgenic clones, the parental line and one negative control (non-targeted) subclone, a single well of DS iPSCs (without dox) was used to generate a cell suspension (cells and small disaggregated clumps). Next, equal aliquots of the cell suspension were plated into each of six wells four times (not relying on one measurement but the average of four for seeding each well). After plating, dox was added to three of the six wells, and the cultures were maintained for 7 d. For images, plates were fixed, stained with 1 mg/ml crystal violet (Sigma) in 70% ethanol for 30 min and scanned to generate TIFF images. For cell counts, single cells were harvested by TryPLE select and counted using Beckman Coulter Z1 Particle Counter.

### Differentiation of neural progenitors and irreversibility in cortical neurons

*Differentiation:* Independent *XIST*-transgenic iPSC clones, and the parental DS iPSC line were dissociated with Accutase (Innovative Cell Technologies) and  $4 \times 10^5$  single cells were plated on Matrigel-coated 6-well plates in mTeSR1 medium (Stemcell technologies). Once the cell culture reached 90%–100% confluence, neural induction was initiated by changing the culture medium to neural induction medium, a 1:1 mixture of N2- and B27-containing media supplemented with 500 ng/ml Noggin (R&D Systems), 10  $\mu$ M SB431542 (Tocris Bioscience), and 1  $\mu$ M retinoic acid (Sigma, cat#: R2625), with/without treatment of dox for the specified times. The neural rosettes were counted and their diameter measured for at least 300 rosettes (sampled in random areas from triplicate dishes). At Day 14, the dox-induced culture had an average rosette diameter of  $142 \mu\text{m} \pm 0.55 \mu\text{m}$  in Clone 1 and  $141 \mu\text{m} \pm 3.49 \mu\text{m}$  in Clone 3. Rosettes could not be measured at the same time point in the uncorrected culture, since they had not formed. At day 17, the uncorrected culture had neural rosettes of similar number and size for both Clones 1 ( $140 \mu\text{m} \pm 0.87 \mu\text{m}$ ) and 3 ( $140 \mu\text{m} \pm 1.09 \mu\text{m}$ ). The corrected culture could not be accurately compared for Day 17 because the rosettes had become so mature and often had merged. After 17 d, neural rosettes were collected by dissociation with Dispase and replated on poly-ornithine and laminin-coated plastic dishes in N2- and B27-containing media including 20 ng/ml FGF2. After a further 2 d, FGF2 was withdrawn to promote differentiation of cortical neurons. *Test of the irreversibility of silencing:* Two independent clones were differentiated to cortical neurons in the presence of dox for 70 days to initiate silencing. They were then split into parallel cultures grown with and without dox for another 30 days, and *XIST* and *APP* expression analyzed by RNA FISH.

## Targeted addition to primary fibroblasts

We used non-immortalized primary human female DS fibroblasts, which like all primary fibroblasts have a limited lifespan in culture (potentially more limited for DS fibroblasts). We reasoned that the robustness of ZFN-driven editing, combined with reduction to disomy for the *DRYK1A* gene, may make it possible to observe some edited cells before they senesce. We used a transgene carrying near full length (~14 kb) *XIST* cDNA under a TetO<sub>2</sub> inducible promoter, and a selectable marker on the same construct, with ~600 bp homology arms to the *DRYK1A* gene (vector is ~21 kb, with a ~17kb insert) (data not shown). When introduced without the Tet-repressor construct, the TetO<sub>2</sub> CMV promoter is constitutively active. Two ZFN containing vectors and the 21 kb *XIST* transgene were transfected into primary DS fibroblasts (Coriell AG13902) using Stemfect polymer (Stemgent) (10:1 ratio of *XIST* to ZFN, and 13 ug DNA to 1.3 ul Stemfect per well of 6-well plate). The frequency of stable integrants was such that a sparse monolayer of transgenic fibroblasts emerged, rather than a few individual colonies following selection with hygromycin (75 ug/ml). The pooled population of selected cells was analyzed by FISH and immunostaining for targeting, *XIST* expression and heterochromatin marks. *XIST* RNA was observed over the *DRYK1A* locus in ~74% of cells, indicating accurate transgene targeting, which was also verified by metaphase FISH (Supplementary Fig. 9c). In many cells there was notable enrichment of H3K27me, UbH2A & H4K20me heterochromatic marks (Supplementary Fig. 9d). Due to the limited lifespan of primary cells and the progressive silencing of the CMV promoter used in this construct, these cells were not more fully characterized.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We appreciate recent initiatives by administrators of NIGMS and NIH to support more high-risk, high-impact research. Research began with support from GM053234 to JBL for basic X chromosome research, and was made fully possible by GM085548 and GM096400 RC4 to JBL. CJB and AMC were supported by CIHR (MOP-13680) to CJB. We thank Terence Flotte for encouragement and advice regarding genome editing strategies, and similarly appreciate the support of Stephen Jones and Peter Newburger. We thank Trevor Collingwood for initial discussions regarding this project, and the George Daley lab (Harvard) for the DS iPSC line. Zdenka Matijasevic, Kelly Smith, Laurie Lizotte and Eric Swanson provided various assistance. Dr. MS Kobor and Lucia Lam (Kobor lab) assisted with methylation analysis. DMC is supported by an NIH fellowship 1F32CA154086 and BRC (O. Rando lab) is supported by NIH training grant 2T32HD007439 (G. Witman, PI).


## References

1. Megarbane A, et al. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. *Genet Med*. 2009; 11:611–616. [PubMed: 19636252]
2. Gardiner KJ. Molecular basis of pharmacotherapies for cognition in Down syndrome. *Trends Pharmacol Sci*. 2010; 31:66–73. [PubMed: 19963286]
3. Prandini P, et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. *Am J Hum Genet*. 2007; 81:252–263. [PubMed: 17668376]
4. Haydar TF, Reeves RH. Trisomy 21 and early brain development. *Trends Neurosci*. 2012; 35:81–91. [PubMed: 22169531]
5. O'Doherty A, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. *Science*. 2005; 309:2033–2037. [PubMed: 16179473]
6. Lee B, Davidson BL. Gene therapy grows into young adulthood: special review issue. *Human molecular genetics*. 2011; 20:R1. [PubMed: 21571785]
7. Hall LL, et al. X-inactivation reveals epigenetic anomalies in most hESC but identifies sublines that initiate as expected. *J Cell Physiol*. 2008; 216:445–452. [PubMed: 18340642]


8. Nazor KL, et al. Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. *Cell Stem Cell*. 2012; 10:620–634. [PubMed: 22560082]
9. Brown CJ, et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. *Cell*. 1992; 71:527–542. [PubMed: 1423611]
10. Clemson CM, McNeil JA, Willard HF, Lawrence JB. XIST RNA paints the inactive X chromosome at interphase: evidence for a novel RNA involved in nuclear/chromosome structure. *J Cell Biol*. 1996; 132:259–275. [PubMed: 8636206]
11. Heard E. Delving into the diversity of facultative heterochromatin: the epigenetics of the inactive X chromosome. *Curr Opin Genet Dev*. 2005; 15:482–489. [PubMed: 16107314]
12. Hall LL, Lawrence JB. XIST RNA and architecture of the inactive X chromosome: implications for the repeat genome. *Cold Spring Harb Symp Quant Biol*. 2010; 75:345–356. [PubMed: 21447818]
13. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. *Nature*. 2005; 434:400–404. [PubMed: 15772666]
14. Lee JT, Strauss WM, Dausman JA, Jaenisch R. A 450 kb transgene displays properties of the mammalian X-inactivation center. *Cell*. 1996; 86:83–94. [PubMed: 8689690]
15. Hall LL, Clemson CM, Byron M, Wydner K, Lawrence JB. Unbalanced X; autosome translocations provide evidence for sequence specificity in the association of XIST RNA with chromatin. *Hum Mol Genet*. 2002; 11:3157–3165. [PubMed: 12444100]
16. Hall LL, et al. An ectopic human XIST gene can induce chromosome inactivation in postdifferentiation human HT-1080 cells. *Proc Natl Acad Sci U S A*. 2002; 99:8677–8682. [PubMed: 12072569]
17. Moehle EA, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. *Proc Natl Acad Sci U S A*. 2007; 104:3055–3060. [PubMed: 17360608]
18. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet*. 2010; 11:636–646. [PubMed: 20717154]
19. DeKolver RC, et al. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. *Genome Research*. 2010; 20:1133–1142. [PubMed: 20508142]
20. Park IH, et al. Disease-specific induced pluripotent stem cells. *Cell*. 2008; 134:877–886. [PubMed: 18691744]
21. Ait Yahya-Graison E, et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. *Am J Hum Genet*. 2007; 81:475–491. [PubMed: 17701894]
22. Biancotti JC, et al. Human embryonic stem cells as models for aneuploid chromosomal syndromes. *Stem Cells*. 2010; 28:1530–1540. [PubMed: 20641042]
23. Csankovszki G, Nagy A, Jaenisch R. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. *J Cell Biol*. 2001; 153:773–783. [PubMed: 11352938]
24. Cotton AM, et al. Chromosome-wide DNA methylation analysis predicts human tissue-specific X inactivation. *Hum Genet*. 2011; 130:187–201. [PubMed: 21597963]
25. Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. *Brain Pathol*. 2011; 21:361–373. [PubMed: 21040072]
26. Shi Y, et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. *Sci Transl Med*. 2012; 4:124ra129.
27. Lavon N, et al. Derivation of euploid human embryonic stem cells from aneuploid embryos. *Stem cells*. 2008; 26:1874–1882. [PubMed: 18450823]
28. Li LB, et al. Trisomy correction in down syndrome induced pluripotent stem cells. *Cell Stem Cell*. 2012; 11:615–619. [PubMed: 23084023]
29. Doyon JB, et al. Rapid and efficient clathrin-mediated endocytosis revealed in genome-edited mammalian cells. *Nat Cell Biol*. 2011

30. Miller JC, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. *Nat Biotechnol.* 2007; 25:778–785. [PubMed: 17603475]
31. Guschin DY, et al. A rapid and general assay for monitoring endogenous gene modification. *Methods in molecular biology.* 2010; 649:247–256. [PubMed: 20680839]
32. Urnov FD, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature.* 2005; 435:646–651. [PubMed: 15806097]
33. Byron M, Hall LL, Lawrence JB. A multifaceted FISH approach to study endogenous RNAs and DNAs in native nuclear and cell structures. *Curr Protoc Hum Gen.* 2013; Chapter 4(Unit 4):15.
34. Irizarry RA, et al. Summaries of Affymetrix GeneChip probe level data. *Nucleic acids research.* 2003; 31:e15. [PubMed: 12582260]
35. Weber M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. *Nat Genet.* 2007; 39:457–466. [PubMed: 17334365]






**Figure 1. Genome-editing integrates XIST into Chr21 in trisomic iPSCs**  
**a.** Concept for translating dosage compensation to trisomy 21. **b.** XIST construct (19kb): two homologous arms and 14kb XIST cDNA with inducible pTRE3G promoter. **c.** DNA/RNA FISH in interphase DS iPSCs shows XIST overlaps one of three DYRK1A genes in non-expressing cell (top, arrows), and a large XIST RNA territory with DYRK1A after 3 days in dox (bottom, arrows). Scale: 2 μm. **d.** OCT4 immunostaining & XIST RNA FISH in a transgenic colony: highly consistent XIST expression throughout the colony. Scale: 100 μm. **e.** Metaphase DNA FISH shows one targeted Chr21. XIST gene (asterisk and close-up) overlaps one of three DYRK1A genes (arrows).




**Figure 2. *XIST* induces heterochromatin modifications and condensed Chr21 Barr Body**  
**a.** *XIST* RNA recruits heterochromatic epigenetic marks (e.g. UbH2A). Channels separated for indicated cell. **b.** Percentage of *XIST* territories with heterochromatin marks. Mean  $\pm$  SE, 100 nuclei in  $\sim$ 5 colonies. **c.** *XIST* RNA induces “Chr21 Barr Body” visible by DAPI stain (arrow). Scale: 2  $\mu$ m.




**Figure 3. XIST induces long-range silencing in targeted iPSCs**

**a.** RNA FISH. *APP* RNA transcribes from three loci in uninduced cells (Day 0), and is progressively silenced following induction (targeted Chr21, arrows). Scale: 2 μm. **b.** Quantification of *APP* silencing. Mean ± SE, 100 nuclei. **c.** Silencing for four more Chr21-linked genes by RNA FISH. Mean ± SE from 100 nuclei. **d.** Long range silencing of Chr21 genes by *XIST* RNA. *USP25* is ~21 Mb from *XIST* integration site (black arrow).



**Figure 4. Genomic expression and methylation reveal widespread silencing of Chr21**  
**a.** Microarray: expression difference for three transgenic clones in dox versus no dox, compared to disomic line versus trisomic parental line. Total change in gene expression (N=3) per chromosome shows Chr21 “correction” near disomic levels, with only limited changes on other chromosomes. Right Y-axis scaled for percent gene expression change. **b.** Distribution of individual gene repression across Chr21. **c.** Methylation of CpG island promoters. In treated clones, 97% of Chr21 genes increased by at least 5% (2 fold greater than average), compared to none in the parental line. P: parental line; 1: Clone 1; 2: Clone 2.





**Figure 5. “Trisomy correction” effects cell proliferation and neurogenesis**

**a.** One week of *XIST* expression resulted in larger, more numerous colonies (representative sample). **b.** Changes in cell number for parental line (PL), parental line subclone (PL-s), and six transgenic clones (C1–C6). Mean  $\pm$ SE. (n=4–6). **c.** Corrected cultures formed neural rosettes by day 14; trisomic (parental and non-induced) cultures took longer (17days). Scale: 100 $\mu$ m. **e.** Number of rosettes formed on day 14 and day 17. Mean  $\pm$ SE, 10–12 random fields in triplicate. P: parental; C1: Clone 1; C3: Clone 3.